AMAALA Appoints HKS Architects Master Planner of Triple Bay and The Coastal Development
AMAALA, the ultra-luxury destination located along Saudi Arabia’s northwestern coastline, has announced the appointment of international design firm HKS Architects as Master Planner for Triple Bay and The Coastal Development. Set in the Prince Mohammed bin Salman Nature Reserve, AMAALA will bring to life the desires and ambitions of a community passionate about shaping, and living, transformative moments.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200317005108/en/
The Coastal Development at AMAALA (Photo : AETOSWire)
Commenting on the appointment Chief Executive Officer of AMAALA, Nicholas Naples, said: “AMAALA will be a globally recognised destination for arts and culture, as well as one of the most comprehensive, integrative health, wellness, and sports offerings in the world. In partnership with HKS Architects, we look forward to realising our vision for Triple Bay and The Coastal Development by redefining the best in travel through the creation of transformative personal journeys for the world’s most discerning travellers.”
Triple Bay will offer a fully holistic wellness retreat, state-of-the-art diagnostic medical facilities, and authentic treatments influenced by the local environment and traditional practices. The community will be the first truly integrated sports and entertainment community with diagnostics, medical, and transformative wellness combined with learning in a family friendly environment.
With underwater experiences that will immerse guests directly into the natural domain of dolphins, turtles, and untouched coral reefs, Triple Bay is set to become one of the world’s finest diving destinations in the world.
The Coastal Development is set to become the defining hub of contemporary arts in the Middle East, playing host to a dynamic programme of exciting events from the global arts and cultural calendar. Built on philanthropy, the immersive programmes will be creative, practical, and academic with a strong link to the Saudi community.
The Coastal Development will feature an arts museum and cultural district dedicated to keeping ancient crafts alive, along with an amphitheatre for live performances. This stretch of coastline will be a gathering place for a community of influencers and connoisseurs, complete with premium spa facilities, yoga, meditation, in addition to an equestrian centre equipped to offer rehabilitation, high-tech stabling, tournament-grade polo facilities, and instructors.
Master Planning & Design Principal of HKS Architects, Kevin Underwood, said: “The developments at Triple Bay and The Coastal Development offer a once-in-a-career opportunity to shape a new tourism destination from the beginning and it’s a privilege to be involved as Master Planners. We’re bringing together the global expertise of our firm, using our knowledge of designing for healthcare, sports, and other uses allied to many years’ experience of working with luxury hotels and resorts to create something innovative and contemporary. Sustainability in all aspects is at the heart of our design, seamlessly integrating landscape and buildings with the stunning mountain and marine landscape of the Red Sea.”
AMAALA’s trio of communities – Triple Bay, Coastal Development, and The Island – will represent three different sets of experiences for visitors. The destination’s development will be rolled out in three key phases, with completion slated ahead of the realisation of Saudi Vision 2030.
*Source: AETOSWire
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200317005108/en/
Contact information
Hill+Knowlton
Muneira Al Adwani
Senior Account Executive, +97145539543
muneira.aladwani@hkstrategies.com
AMAALA
Julia Gajcak
Head of Communications and Events, +966532580725
jgajcak@projects.pif.gov.sa
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom